BioSpace News Archive

Drug Development

AstraZeneca Ends CLL Study Early After Hitting Endpoints

During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.

June 6, 2019
·
2 min read
·
Alex Keown
Business

States Call for Transparency From PBMs Following Report About Spread Pricing

The report from the state’s Health Policy Commission reveals state spending on prescription drugs nearly doubled from $1.1 billion to $1.9 billion over a five year period.

June 6, 2019
·
2 min read
·
Alex Keown
Biotech Bay

Research Roundup: Heart Disease Mutations, Depression and Huntington’s and More

Here are some of the top research stories that happened around the industry this week.

June 6, 2019
·
7 min read
·
Mark Terry
Business

BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More

With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.

June 6, 2019
·
7 min read
·
Mark Terry
Business

BioSpace Movers and Shakers, June 7

Pharma and biotech companies strengthen their executive and leadership teams with new appointments.

June 6, 2019
·
6 min read
·
Alex Keown
Genetown

First Light Diagnostics to Showcase MultiPath™ Platform at ASM Microbe 2019

First Light Diagnostics announced its participation at the American Society for Microbiology’s ASM Microbe 2019 Event in San Francisco, California, from June 20-24.

June 6, 2019
·
2 min read
Drug Development

Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes

Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.

June 6, 2019
·
8 min read
BioCapital

ArcheMedX to Reveal Ready, an Operational Intelligence and Workforce Readiness Platform, at DIA 2019 Global Annual Meeting

ArcheMedX is pleased to announce the launch of Ready, a new digital platform to reduce the risks and costs associated with under-performing clinical trials, at this year’s Drug Information Association Global Annual Meeting from June 23-27 in San Diego, CA.

June 6, 2019
·
2 min read
Business

Hamilton And Enable Biosciences Team Up to Automate Ultra-Sensitive Antibody Detection Assay Platform

Hamilton Company and Enable Biosciences are pleased to announce their collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow.

June 6, 2019
·
4 min read
Drug Development

First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava

Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting

June 6, 2019
·
7 min read